1. Home
  2. SRV vs EOLS Comparison

SRV vs EOLS Comparison

Compare SRV & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NXG Cushing Midstream Energy Fund of Beneficial Interest

SRV

NXG Cushing Midstream Energy Fund of Beneficial Interest

HOLD

Current Price

$40.15

Market Cap

184.9M

Sector

Finance

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$6.99

Market Cap

444.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRV
EOLS
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.9M
444.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SRV
EOLS
Price
$40.15
$6.99
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.80
AVG Volume (30 Days)
33.9K
1.1M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
13.38%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$285,823,000.00
Revenue This Year
N/A
$14.36
Revenue Next Year
N/A
$23.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.10
52 Week Low
$30.73
$5.71
52 Week High
$44.30
$17.12

Technical Indicators

Market Signals
Indicator
SRV
EOLS
Relative Strength Index (RSI) 40.20 52.83
Support Level $39.28 $6.83
Resistance Level $41.21 $7.29
Average True Range (ATR) 0.87 0.25
MACD -0.04 0.01
Stochastic Oscillator 26.51 68.82

Price Performance

Historical Comparison
SRV
EOLS

About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest

NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: